General
Preferred name
PIRENZEPINE
Synonyms
PIRENZEPINE HYDROCHLORIDE ()
Pirenzepine dihydrochloride ()
Pirenzepine HCl ()
Bisvanil ()
Tabe ()
LS519 ()
[3H]pirenzepine ()
Pirenzepine (dihydrochloride) ()
LS 519 ()
Pirenzepin (dihydrochloride) ()
Gastrozepin (dihydrochloride) ()
LS 519 (free base) ()
Pirenzepin ()
Gastrozepin ()
NSC-757846 ()
LS 519 C12 ()
LS-519 CL2 ()
LS-519CL2 ()
LS 519 CL2 ()
ACI-91 ()
Wst-057 ()
9110700 ()
Pirenzepina ()
350320 ()
Gastri P ()
[3H]pirenzepine ()
Pirenzepine (hydrochloride) ()
P&D ID
PD009857
CAS
29868-97-1
28797-61-7
Tags
available
drug candidate
drug
biased GPCR ligand
Drug indication
Peptic ulcer
Discovery agent
Drug Status
approved
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells[1][2].
DESCRIPTION Pirenzepine muscarinic acetylcholine receptor antagonist, selective for the M1 receptor subtype. (GtoPdb)
DESCRIPTION Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells[1][2].
DESCRIPTION Selective M1 muscarinic acetylcholine receptor antagonist (LOPAC library)
DESCRIPTION Selective group II mGlu antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist, inhibiting gastric secretion. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
28
BiasDB
Pirenzepine
Cayman Chemical Bioactives
29527
ChEMBL Drugs
CHEMBL1531864
CHEMBL9967
Concise Guide to Pharmacology 2017/18
3272
Concise Guide to Pharmacology 2019/20
3272
Concise Guide to Pharmacology 2021/22
328
3272
Concise Guide to Pharmacology 2023/24
328
3272
Drug Repurposing Hub
DrugBank
DB00670
DrugBank Approved Drugs
DB00670
DrugCentral
2200
DrugCentral Approved Drugs
2200
DrugMAP
DMP6M1N
DMAMD5H
DrugMAP Approved Drugs
DMP6M1N
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101420
Guide to Pharmacology
328
3272
Ki Database
PIRENZEPINE
LOPAC library
MedChem Express Bioactive Compound Library
HY-17037
HY-17037A
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
pirenzepine-dihydrochloride
TargetMol Bioactive Compound Library
T1542
The Spectrum Collection
Tocris Bioactive Compound Library
1071
External IDs
58
Properties
(calculated by RDKit )
Molecular Weight
351.17
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
2
cLogP
1.56
TPSA
68.78
Fraction CSP3
0.32
Chiral centers
0.0
Largest ring
7.0
QED
0.89
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
M1
Target
mAChR
CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AChR
Primary Target
M1 Receptors
MOA
Antagonist
Muscarinic M1 Antagonists
acetylcholine receptor antagonist
Member status
member
Indication
peptic ulcer disease (PUD)
Pathway
Neuroscience
GPCR/G protein
Neuronal Signaling
Therapeutic Class
Antiulcer Agents
Source data